CORPORATE FACT SHEET

OVERVIEW: Gen-Probe is a leader in molecular diagnostics used for diagnosing infectious diseases, screening donated blood, assessing immune response for transfusion, measuring components of the coagulation pathway, helping ensure transplant compatibility, and aiding biomedical research/drug development. Gen-Probe has more than 29 years of molecular diagnostics expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing nucleic acid tests and systems for blood screening. Gen-Probe is headquartered in San Diego and employs over 1,400 people. For more information, please visit www.gen-probe.com.

KEY DIAGNOSTICS PRODUCTS:
- APTIMA COMBO 2® Assay, APTIMA® CT Assay and APTIMA® GC Assay for the detection of Chlamydia and gonorrhea
- APTIMA® HIV-1 and HCV Qualitative Assays for HIV-1 and hepatitis C
- APTIMA® HPV Assay
- APTIMA® Trichomonas vaginalis Assay
- PACE® Assays for the detection of Chlamydia and gonorrhea
- ACCUPROBE® Culture Identification Tests
- AMPLIFIED MTD® (Mycobacterium Tuberculosis Direct) Test
- GASDirect® to detect Group A Streptococcus
- PROGENSA® PCA3 Assay
- LIFECODES® products for specialty coagulation, HLA immunology for transplantation and transfusion medicine
- Elucigene™ Genetic Disease Testing products (Europe only)

KEY BLOOD SCREENING PRODUCTS:
- PROCLEIX® HIV-1/HCV Assay
- PROCLEIX® WNV (West Nile Virus) Assay
- PROCLEIX® ULTRIO™ Assay for HIV-1, HCV and HBV

ADDITIONAL PRODUCTS AND SERVICES:
- Diaclone™ Immunology Products
- Nucleon™ DNA Extraction
- Tepnel™ Pharmaceutical Services

HISTORY:
1983: Company founded
1985: Introduced first FDA-approved NAT, for Legionnaire’s disease
1988: Launched PACE®
2001: Launched APTIMA COMBO 2
2002: Spun off as independent company from Chugai Pharmaceutical Co.
2002: Received FDA approval for Procleix® HIV-1/HCV blood screening assay
2004: Introduced TIGRIS® DTS® System; first fully-automated, high-throughput molecular diagnostics instrument
2005: Awarded the National Medal of Technology
2006: Launched PROGENSA® PCA3 (CE marked; currently in review by the FDA in the US)
2007: Received FDA approval for West Nile Virus blood screening assay on the TIGRIS® DTS® System
2008: Launched APTIMA® HPV Assay (CE marked; currently in review by the FDA in the US)
2009: Extended and expanded blood screening collaboration with Novartis through 2025; Acquired Tepnel Life Sciences plc and Prodesse, Inc.; received FDA clearance for Prodesse® ProParflu™+ in the US
2010: Strategic investment in Pacific Biosciences, generation sequencing company; launched PANTHER™ System in Europe; received FDA clearance and CE mark for Prodesse® ProFAST™+ and ProAdeno™+
2011: Acquired GTI Diagnostics, Inc., APTIMA® Trichomonas vaginalis assay (CE-marked, and FDA cleared), APTIMA® HPV mRNA assay (CE-marked, and FDA approved)
2012: PROGENSA® PCA3 Assay (CE-marked, FDA approved, Health Canada cleared)

MANAGEMENT:
- Carl Hull, Chairman of the Board and Chief Executive Officer
- Daniel Kacian, MD, PhD, Executive Vice President, Chief Scientist
- R. William Bowen, Senior Vice President, General Counsel and Secretary
- Diana De Walt, Senior Vice President, Human Resources
- Jorgine Ellerbrock, Senior Vice President, Operations
- Paul Gargan, PhD, Senior Vice President, Business Development
- Brian Hansen, Senior Vice President, Global Sales and Service
- Herm Rosenman, Senior Vice President, Finance and Chief Financial Officer
- Eric Tardif, Senior Vice President, Corporate Development and Marketing
- Christina Yang, PhD, CQA, RAC, Senior Vice President, Regulatory & Quality

Contact:
Michael Watts
Vice president, investor relations and corporate communications
Gen-Probe Incorporated
858-410-8673

Alyssa Eggum
Director, Global MarCom and Branding
Gen-Probe Incorporated
858-410-8647

PROCLEIX and ULTRIO are trademarks of Novartis Vaccines and Diagnostics. All other trademarks are property of Gen-Probe.